Britannia Life Sciences Inc. (CSE:BLAB)
Canada · Delayed Price · Currency is CAD 0.0700
0.00 (0.00%)
Sep 17, 2026, 5:14 PM EST
Britannia Life Sciences Ratios and Metrics
Market cap in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 12 | 15 | 12 | 11 | 15 | 31 | |
Market Cap Growth | 9.24% | 20.00% | 7.14% | -26.32% | -49.89% | - |
Enterprise Value | -1 | -1 | 23 | 21 | 25 | 38 |
Last Close Price | 0.07 | 0.09 | 0.07 | 0.07 | 0.10 | 0.19 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 0.76 | 1.00 | 1.65 | - | 3.03 | - |
PS Ratio | 28.35 | 30.75 | 32.95 | 21.98 | 2.41 | 4.21 |
PB Ratio | 0.52 | 0.70 | 1.93 | 1.70 | 1.39 | 5.61 |
P/TBV Ratio | 0.52 | 0.70 | 1.93 | - | - | - |
P/FCF Ratio | - | - | - | 5.43 | 7.89 | 11.34 |
P/OCF Ratio | - | - | - | 5.43 | 7.68 | 10.99 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | - | - | 62.12 | 40.45 | 3.90 | 5.26 |
EV/EBITDA Ratio | - | - | - | - | 22.64 | 21.88 |
EV/EBIT Ratio | - | - | - | - | 25.15 | 23.75 |
EV/FCF Ratio | - | - | - | 9.99 | 12.80 | 14.15 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.30 | 1.09 | 0.76 | 0.95 |
Debt / EBITDA Ratio | - | - | - | - | 7.31 | 2.88 |
Debt / FCF Ratio | - | - | - | 3.48 | 4.31 | 1.92 |
Net Debt / Equity Ratio | -0.55 | -0.81 | -0.95 | 0.89 | 0.53 | 0.65 |
Net Debt / EBITDA Ratio | 8.78 | 12.13 | 2.78 | -4.19 | 5.26 | 2.03 |
Net Debt / FCF Ratio | 31.29 | 14.62 | 2.29 | 2.85 | 2.98 | 1.31 |
Asset Turnover | 0.02 | 0.03 | 0.02 | 0.02 | 0.29 | 0.34 |
Quick Ratio | 5.49 | 6.39 | 2.21 | 0.24 | 0.91 | 0.41 |
Current Ratio | 5.69 | 6.57 | 2.72 | 0.26 | 0.92 | 0.42 |
Return on Equity (ROE) | 108.44% | 96.67% | -70.32% | -68.98% | 70.57% | -343.40% |
Return on Assets (ROA) | -5.24% | -5.13% | -8.18% | -4.23% | 2.78% | 4.75% |
Return on Invested Capital (ROIC) | -20.53% | -67.57% | -34.23% | -10.50% | 7.65% | 15.08% |
Return on Capital Employed (ROCE) | -6.50% | -6.90% | -27.80% | -13.20% | 5.20% | 12.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 143.57% | 100.33% | 60.75% | -41.98% | 32.98% | -50.26% |
FCF Yield | -3.38% | -7.92% | -21.53% | 18.42% | 12.67% | 8.82% |
Buyback Yield / Dilution | - | - | - | -0.07% | -48.07% | -41.06% |